Skip to Main Content
Skip Nav Destination

Co-crystals are used to overcome the limitations of poor solubility and poor oral bioavailability of pharmaceuticals. The multiple components of co-crystals are interacting non-covalently with solvent where API properties are improved. The current research mainly focuses on formulating and evaluating Gabapentin (GBP) cocrystals with various coformers like L-Ascorbic acid and Acetyl salicylic acid. The current study of Novel co-crystals is prepared by using the co-grinding method in different stoichiometric ratios of 1:1 and 1:3. FTIR, PXRD, SEM, flow characteristics, inherent solubility, and in vitro dissolution are used to describe synthesized crystals. The FTIR analysis was interpreted that Gabapentin forms a hydrogen bond with the complimentary carboxyl groups of L-Ascorbic acid and Acetyl salicylic acid. PXRD analyses of GBP-L-ASC CF are showing a high degree of Crystallinity compared to other co-former Cocrystals. Flow properties for prepared Cocrystals are showing excellent while compared to pure drug. Particle size analysis by SEM revealed that 1:3 ratio prepared Cocrystals (GBP-ASA CF-2, and GBP-ASA CF-4) showed less size than 1:1 ratio prepared Cocrystals. GBP-ASA CF-2 and GBP-ASA CF-4 showed 44.63 folds and 59.12 folds increased solubility. The invitro dissolution test showed that GBP-ASA CF-4 and GBP-ASC CF-2 showed a higher dissolution rate (99.87%, and 97.84%) than pure Gabapentin. GBP-ASA CF-4 and GBP-ASC CF-2 showed modification in the chemical environment, intermolecular interactions were established, and improved flow properties with enhanced intrinsic solubility and invitro dissolution rate than a pure drug by decreasing Cocrystals particle size.

This content is only available via PDF.
You do not currently have access to this chapter, but see below options to check access via your institution or sign in to purchase.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal